Adcock Ingram Holdings Ltd banner
A

Adcock Ingram Holdings Ltd
JSE:AIP

Watchlist Manager
Adcock Ingram Holdings Ltd
JSE:AIP
Watchlist
Price: 7 480.0003 Zac Market Closed
Market Cap: 12.1B ZAR

EV/IC

1.9
Current
26%
More Expensive
vs 3-y average of 1.5

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.9
=
Enterprise Value
Zac12.2B
/
Invested Capital
6.3B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.9
=
Enterprise Value
Zac12.2B
/
Invested Capital
6.3B

Valuation Scenarios

Adcock Ingram Holdings Ltd is trading above its 3-year average

If EV/IC returns to its 3-Year Average (1.5), the stock would be worth Zac5 958.73 (20% downside from current price).

Statistics
Positive Scenarios
1/3
Maximum Downside
-24%
Maximum Upside
+124%
Average Upside
27%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.9 Zac7 480
0%
3-Year Average 1.5 Zac5 958.73
-20%
5-Year Average 1.5 Zac5 663.66
-24%
Country Average 4.4 Zac16 788.69
+124%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
ZA
Adcock Ingram Holdings Ltd
JSE:AIP
12.1B ZAR 1.9 14.1
US
Eli Lilly and Co
NYSE:LLY
883B USD 9.2 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 3.5 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 3.7 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 2.6 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 2.9 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 2.6 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 1.1 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2 17.3
P/E Multiple
Earnings Growth PEG
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average P/E: 21.5
14.1
6%
2.3
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

In line with most companies in South Africa
Percentile
46th
Based on 21 companies
46th percentile
1.9
Low
0.2 — 0.9
Typical Range
0.9 — 4.4
High
4.4 —
Distribution Statistics
South Africa
Min 0.2
30th Percentile 0.9
Median 4.4
70th Percentile 4.4
Max 21.4

Adcock Ingram Holdings Ltd
Glance View

Market Cap
12.1B Zac
Industry
Pharmaceuticals

Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.

AIP Intrinsic Value
6 641.1914 Zac
Overvaluation 11%
Intrinsic Value
Price Zac7 480.0003
A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett